Chandra Bhagat Pharma Approves ₹29 Crore Preferential Warrant Issue

Board approved a preferential issue of up to 66 lakh convertible warrants at Rs 44 each, aggregating up to Rs 29.04 Cr, to promoters, promoter group and non-promoter investors. Warrants carry a 1:1 conversion ratio, 18-month exercise period and 25% upfront payment, subject to shareholder approval. Authorized share capital will increase from Rs 8.5 Cr to Rs 15 Cr.